|Antibody Name:||PM-1 (VH SGII | kI)|
Sato, K., Tsuchiya, M., Saldanha, J., Koishihara, Y., Ohsugi, Y., Kishimoto, T. and Bendig, M.M.
"Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth"
Canc. Res. (1994) 53:851-856.
Tsunenari, T., Akamatsu, K., Kaiho, S., Sato, K., Tsuchiya, M., Koishihara, Y., Kishimoto, T. and Ohsugi, Y. "Therapeutic potential of humanized anti-interleukin-6 receptor antibody: Antitumor activity in xenograft model of multiple myeloma" Anticancer Res. (1996) 16:2537.
|Acceptor Antibody:||Human IgG1 | k|
|Antigen:||human interleukin 6 receptor|
|Laboratory:||Chugai Pharmaceutical Co. & Osaka University Medical School, Japan; MRC Collaborative Centre, UK|
|Design:||Homology search revealed VH VAP (SGII) and VL REI (SGI). A model was built of the mouse variable regions. Six versions of the heavy chain and 2 of the light chain.|
|Frameworks:||VH NEWM | VL REI (from D1.3)|
|CDRs:||All 6 VH and VL, Kabat Definition.|
VH STFS27-30YSIT V71R
VL none (except those of Riechmann et al, (1988)).
|Binding:||Best binder, version VH(f)| VL(a) by competition binding assays. Binds "as well as" chimaeric and mouse mAbs. Inhibits growth of multiple myeloma cells.|
|Expression:||Transient expression in cos cells with human elongation factor (HEF) vectors; stable expression in CHO DHFR- cells|
In heavy chain, position 1
and 48 also tested but no influence on binding.
F71:L kept human, Y in mouse caused worse binding!
|Clinical Indication:||Multiple myeloma patients. The disease is always lethal and few therapeutic treatments are available.|
|José Saldanha © 1997-8. Birkbeck College, London WC1E 7HX.|